Plain-English translation of NCT07380204 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial tests a new imaging method called [11C]HSP990 PET scanning to measure a protein called Hsp90 in the human brain. Hsp90 is a protein that helps other proteins in your brain stay healthy and work properly. The study involves healthy volunteers and people diagnosed with Parkinson's disease, Alzheimer's disease, or amyotrophic lateral sclerosis (ALS) to see if this imaging method can detect differences in Hsp90 levels between healthy and diseased brains.
In diseases like Parkinson's, Alzheimer's, and ALS, proteins in the brain misfold and clump together, damaging nerve cells. Scientists believe that Hsp90 could be a key target for new treatments to prevent this protein damage. This imaging method could help doctors measure Hsp90 levels in patients' brains and test whether new medications designed to boost this protective protein actually work.
You likely qualify if…
You likely don't qualify if…
If you are a healthy volunteer, you will have one or more PET/CT brain imaging scans that last about 2 hours total, with possible breaks during the scan. Some participants will also have blood samples taken from an artery to measure how the tracer moves through your body. If you have Parkinson's disease, Alzheimer's disease, or ALS, you will undergo similar brain imaging scans. All scans are non-invasive and painless, though you will receive a small injection of the radioactive tracer beforehand.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
Belgium